Eiger BioPharmaceuticals to Participate in Investor Conferences
Details of September Investor Conferences:
- B.
Riley FBR Healthcare Conference ,September 4, 2018 at theMarriott New York Eastside Hotel . Panel: "Hepatitis B Functional Cure Cannot Be Improved",9:50 - 10:50 AM ET ,Stuyvesant Room . Eiger will host one-on-one meetings. H.C. Wainwright 20th AnnualGlobal Investment Conference at theSt. Regis Hotel ,New York City . Corporate PresentationSeptember 6, 2018 ,5:05 PM ET . Eiger will host one-on-one meetings.- BioCentury NewsMakers in the
Biotech Industry Conference at theMillenium Broadway Hotel & Conference Center ,New York City . Corporate PresentationSeptember 7, 2018 ,1:30 PM ET . Eiger will host one-on-one meetings.
A live webcast of the
About Eiger
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. Our lead program in Hepatitis Delta Virus (HDV) infection is advancing into Phase 3 with a single, pivotal trial (D-LIVR Study) planned to initiate by the end of 2018. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors:
Email: [email protected] / Phone: 1-650-619-6115
View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-investor-conferences-300702442.html
SOURCE